Peptide Based In Vitro Diagnostics | Bachem AG | Video

Bachem Reports Slight H1 2024 Sales Growth And Confirms Full-Year Outlook

25 Jul 2024

// PRESS RELEASE

Incident On Construction Site Of Bachem In Bubendorf

28 May 2024

// PRESS RELEASE

Voices On Bachem’S Innovation Culture

30 Apr 2024

// PRESS RELEASE

DATA COMPILATION
#PharmaFlow

Contact Supplier

Website

Boulder Peptide 2024

Presentation on Day 3

Book a meeting

envelop Contact Supplier

DIGITAL CONTENT

39 CORPORATE CONTENT #SupplierSpotlight, 2 DATA COMPILATION #PharmaFlow, 119 NEWS #PharmaBuzz

media
39 CORPORATE CONTENT #SupplierSpotlight
2 DATA COMPILATION #PharmaFlow
119 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

47 All APIs, 36 USDMF, 12 CEP/COS, 11 JDMF, 11 KDMF, 49 NDC API, 6 VMF, 28 Listed APIs

47 All APIs
36 USDMF
12 CEP/COS
11 JDMF
11 KDMF
49 NDC API
6 VMF
28 Listed APIs

KEY PRODUCTS

Atosiban, Bivalirudin, Glucagon, Glucagon Hydrochloride, Goserelin Acetate, Lanreotide Acetate, Leuprolide Acetate, Leuprolide Mesylate, Octreotide Acetate, Propofol, Semaglutide, Teriparatide, Teriparatide Acetate, Triptorelin Acetate, Triptorelin Pamoate

Atosiban
Bivalirudin
Glucagon
Glucagon Hydrochloride
Goserelin Acetate
Lanreotide Acetate
Leuprolide Acetate
Leuprolide Mesylate
Octreotide Acetate
Propofol
Semaglutide
Teriparatide
Teriparatide Acetate
Triptorelin Acetate
Triptorelin Pamoate

SERVICES

Analytical, API Manufacturing, API & Drug Product Development

pharmaServices
Analytical
- 1 Analytical Method Development
API Manufacturing
API & Drug Product Development
- 3 API Development

KEY SERVICES

Custom Peptide Synthesis, CMO for Peptide & Oligonucleotide APIs

Custom Peptide Synthesis
CMO for Peptide & Oligonucleotide APIs

INSPECTIONS & REGISTRATIONS

33 FDA, 3 EDQM, 5 GDUFA, 8 Others

inspections
33 FDA
3 EDQM
5 GDUFA
8 Others

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

About

With more than 50 years of experience and expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide, providing a wide range of services. Over the years, Bachem has established itself as a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company is headquartered in Switzerland and has offices in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.